Oculaphenicol D (Chloramphenicol, Dexamethasone)

Chloramphenicol, the active ingredient in Oculaphenicol D, is an antibiotic presented as an ophthalmic solution for topical eye use. It treats bacterial eye infections and reduces inflammation when combined with a corticosteroid. Dexamethasone, the second active ingredient, is a corticosteroid that provides anti‑inflammatory action in the same formulation.

GNH USA supplies Oculaphenicol D as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Oculaphenicol D is used for ocular conditions where bacterial infection and inflammation coexist. - Bacterial conjunctivitis: reduces bacterial load and alleviates redness and discharge. - Keratitis (bacterial): helps eradicate infection and limits corneal inflammation. - Post‑operative ocular inflammation: controls inflammation while preventing secondary bacterial infection. - Allergic or irritative conjunctivitis with suspected bacterial component: provides symptom relief and antimicrobial coverage.

Oculaphenicol D may cause local ocular reactions and, rarely, systemic effects.

Common Side Effects: - Burning or stinging sensation: mild discomfort upon instillation. - Redness or mild irritation: transient conjunctival hyperemia. - Blurred vision: temporary visual disturbance that resolves after blinking. - Tearing: increased lacrimation shortly after use.

Serious or Rare Side Effects: - Allergic contact dermatitis: localized swelling, itching, or rash. - Secondary ocular infection: overgrowth of resistant organisms. - Elevated intra‑ocular pressure: possible with prolonged corticosteroid exposure. - Systemic toxicity: rare systemic absorption leading to bone marrow suppression (chloramphenicol).

Before using Oculaphenicol D, consider the following precautions: - Contraindication: known hypersensitivity to chloramphenicol, dexamethasone, or formulation excipients. - Caution in viral eye infections: corticosteroid component may worsen viral replication. - Use limited duration: prolonged use can increase risk of intra‑ocular pressure rise. - Monitor in diabetic patients: corticosteroids may affect glucose control. - Avoid in children under 2 years: risk of systemic chloramphenicol toxicity. - Store at room temperature: keep in original container, protect from light and moisture.

Ocular drugs can interact with systemic or topical agents, affecting efficacy or safety.

Major Interactions (Avoid): - Systemic aminoglycosides: may increase risk of ototoxicity when combined with corticosteroids. - Systemic anticoagulants: corticosteroids can potentiate bleeding risk.

Moderate Interactions (Monitor Closely): - Other ophthalmic NSAIDs or steroids: additive anti‑inflammatory effect may raise intra‑ocular pressure. - Systemic CYP3A4 inducers: may reduce dexamethasone exposure. - Topical ocular antibiotics: overlapping antimicrobial spectrum may select resistant flora.